检索结果 - Langmuir, Peter

JAK inhibitors and COVID-19 由 Levy, Gabriel, Guglielmelli, Paola, Langmuir, Peter, Constantinescu, Stefan N

获取全文 获取全文 获取全文

Design of Clinical Trials Evaluating Ruxolitinib, a JAK1/JAK2 Inhibitor, for Treatment of COVID-19–Associated Cytokine Storm 由 Langmuir, Peter, Yeleswaram, Swamy, Smith, Paul, Knorr, Barbara, Squier, Peg

获取全文 获取全文 获取全文

Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment 由 Yeleswaram, Swamy, Smith, Paul, Burn, Timothy, Covington, Maryanne, Juvekar, Ashish, Li, Yanlong, Squier, Peg, Langmuir, Peter

获取全文 获取全文 获取全文

Th1 cytokines, programmed cell death, and alloreactive T cell clone size in transplant tolerance 由 Kishimoto, Koji, Sandner, Sigrid, Imitola, Jaime, Sho, Masayuki, Li, Yongsheng, Langmuir, Peter B., Rothstein, David M., Strom, Terry B., Turka, Laurence A., Sayegh, Mohamed H.

获取全文 获取全文 获取全文

Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients With Non–Small-Cell Lung Cancer 由 Hanrahan, Emer O., Lin, Heather Y., Kim, Edward S., Yan, Shaoyu, Du, Danny Z., McKee, Kathryn S., Tran, Hai T., Lee, J. Jack, Ryan, Anderson J., Langmuir, Peter, Johnson, Bruce E., Heymach, John V.

获取全文 获取全文 获取全文

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses 由 Verstovsek, Srdan, Gotlib, Jason, Mesa, Ruben A., Vannucchi, Alessandro M., Kiladjian, Jean-Jacques, Cervantes, Francisco, Harrison, Claire N., Paquette, Ronald, Sun, William, Naim, Ahmad, Langmuir, Peter, Dong, Tuochuan, Gopalakrishna, Prashanth, Gupta, Vikas

获取全文 获取全文 获取全文

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial 由 Wells, Samuel A., Robinson, Bruce G., Gagel, Robert F., Dralle, Henning, Fagin, James A., Santoro, Massimo, Baudin, Eric, Elisei, Rossella, Jarzab, Barbara, Vasselli, James R., Read, Jessica, Langmuir, Peter, Ryan, Anderson J., Schlumberger, Martin J.

获取全文 获取全文 获取全文

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial 由 Herbst, Roy S, Sun, Yan, Eberhardt, Wilfried E E, Germonpré, Paul, Saijo, Nagahiro, Zhou, Caicun, Wang, Jie, Li, Longyun, Kabbinavar, Fairooz, Ichinose, Yukito, Qin, Shukui, Zhang, Li, Biesma, Bonne, Heymach, John V, Langmuir, Peter, Kennedy, Sarah J, Tada, Hiroomi, Johnson, Bruce E

获取全文 获取全文 获取全文

A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease 由 Schroeder, Mark A., Khoury, H. Jean, Jagasia, Madan, Ali, Haris, Schiller, Gary J., Staser, Karl, Choi, Jaebok, Gehrs, Leah, Arbushites, Michael C., Yan, Ying, Langmuir, Peter, Srinivas, Nithya, Pratta, Michael, Perales, Miguel-Angel, Chen, Yi-Bin, Meyers, Gabrielle, DiPersio, John F.

获取全文 获取全文 获取全文

Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 tri... 由 Han, MeiLan K, Antila, Martti, Ficker, Joachim H, Gordeev, Ivan, Guerreros, Alfredo, Bernus, Amparo Lopez, Roquilly, Antoine, Sifuentes-Osornio, José, Tabak, Fehmi, Teijeiro, Ricardo, Bandelli, Lorraine, Bonagura, Diane S, Shu, Xu, Felser, James M, Knorr, Barbara, Cao, Weihua, Langmuir, Peter, Lehmann, Thomas, Levine, Michael, Savic, Sinisa

获取全文 获取全文 获取全文